Insider Buying: Medicenna Therapeutics (TSE:MDNA) Insider Acquires C$11,200.00 in Stock

Medicenna Therapeutics Corp. (TSE:MDNA) insider David Hyman purchased 10,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was purchased at an average cost of C$1.12 per share, with a total value of C$11,200.00. Following the acquisition, the insider directly owned 50,000 shares in the company, valued at C$56,000. This trade represents a 25.00% increase in their ownership of the stock.

Medicenna Therapeutics Stock Performance

Shares of Medicenna Therapeutics stock opened at C$1.08 on Thursday. The stock’s fifty day simple moving average is C$1.33 and its 200 day simple moving average is C$1.09. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88. The company has a market capitalization of C$90.08 million, a PE ratio of -6.35 and a beta of 3.31. Medicenna Therapeutics Corp. has a 12 month low of C$0.78 and a 12 month high of C$1.98.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings results on Thursday, November 13th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative return on equity of 159.88% and a negative net margin of 533,640.00%. On average, research analysts predict that Medicenna Therapeutics Corp. will post -0.37 EPS for the current year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.